TAG:
laboratory testing services
Anticipating Washington’s Next Blows to Lab Testing
By Robert Michel | From the Volume XX No. 4 – March 25, 2013 Issue
CEO SUMMARY: With the advent of 2013, almost every lab was responding to some type of price cut. Clinical labs are dealing with the sequential, multi-year cuts to the Medicare Part B Lab Test Price Schedule. Anatomic pathology labs are still adjusting to the expiration of the TC Grandfath…
Lawyers Share Insights about ACO Contracting
By Joseph Burns | From the Volume XX No. 2 February 11, 2013 Issue
CEO SUMMARY: Most pathologists have yet to be involved in any substantial contractual negotiations that would allow them to assume a significant role in accountable care organizations (ACOs). Instead, hospitals and health systems are putting the building blocks in place by acquiring physi…
Manhattan Labs Gets Infusion of Equity Cash
By Joseph Burns | From the Volume XX No. 2 February 11, 2013 Issue
CEO SUMMARY: Manhattan Labs tapped a private equity company for growth capital last month. The company says its strategy is to deliver concierge-level quality lab services to the high-end physicians and patients within the tri-state area of New York, New Jersey, and Connecticut. These are…
Anticipating 2013 Trends in Clinical Lab and Pathology
By Robert Michel | From the Volume XX No. 1 – January 22, 2013 Issue
CEO SUMMARY: Biggest news for 2013 will the impact of significant price cuts for both clinical lab and anatomic pathology testing services. But the bad news doesn’t stop there. Employers and private payers will be more aggressive in taking steps to reduce what they spend on lab testing….
2012’s Top Ten Lab Stories Predict More Challenges
By Robert Michel | From the Volume XIX No. 18 – December 31, 2012 Issue
CEO SUMMARY: It’s been a year with more lows than highs, when viewed through the lens of THE DARK REPORT’S “Top Ten Lab Stories of 2012.” The end of the TC grandfather clause, new policies for prostate biopsy billing, and a dramatic 52% cut to 88305- TC fees were widely reported. …
Finding Lab Growth Opportunities Amid the Gloom
By R. Lewis Dark | From the Volume XIX No. 18 – December 31, 2012 Issue
IN MANY WAYS, THE TRADITIONAL BUSINESS MODELS for laboratory testing services are proving deficient in the face of a swiftly-evolving healthcare system. I suspect that none of us fully understand how many laboratory organizations are already under extreme financial stress. We intuitively understand …
RDX Alters Business Plan Due to Lab Market Changes
By Joseph Burns | From the Volume XIX No. 17 – December 10, 2012 Issue
CEO SUMMARY: Executives at Regional Diagnostic Laboratories (RDX) made a splash last May when they announced the new company’s plans to acquire hospital laboratory outreach programs, backed by a capital commitment of $250 million. Now, in recognition of swift changes in the lab test mar…
Louisiana Pathologists ‘Moonlight’ as Consultants
By Joseph Burns | From the Volume XIX No. 15 – October 29, 2012 Issue
CEO SUMMARY: Few independent pathology groups have developed robust laboratory consulting businesses. But adopting that strategy has brought important benefits to Delta Pathology Group, LLC, of Shreveport, Louisiana. Not only has providing lab consulting services to cash-strapped hospital…
Competitive Bidding: Once Again, It’s Back!
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: For the clinical lab industry, the concept of competitive bidding for Medicare Part B Clinical Lab Testing may be like the movie “Groundhog Day.” The hero, Bill Murray, kept reliving the same day over and over. So it seems to be with competitive bidding. In the latest rep…
Narrower Provider Networks Topic during Quest Conference Call
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
SINCE MAY 1, 2012, the nation’s largest clinical laboratory company has had a new CEO, who is Stephen H. Rusckowski. The company’s second quarter conference call provided an opportunity to learn more about how he views Quest Diagnostics Incorporated. Conducted on July 19, the fi…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized